SCN8A

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Central nervous system, Quarter, EMA, Focal seizure, Research, New Drug Application, UCB, FDA, Partnership, Food, Part, Quantitative electroencephalography, SCN8A, Tremor, SCN2A, Safety, PPR, European Medicines Agency, CNS, EEG, Pharmacokinetics, Part 1, Patient, Essential tremor, Medicine, Epilepsy, DEE, Trial of the century, NDA, Ageing, Central nervous system disease, Seizure, Pharmaceutical industry

Fourth Quarter and Full Year 2023 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    As of December 31, 2023, Praxis had $81.3 million in cash and cash equivalents, compared to $100.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
  • Research and development expenses were $18.4 million for the fourth quarter of 2023, compared to $28.3 million for the fourth quarter of 2022.
  • General and administrative expenses were $9.9 million for the fourth quarter of 2023, compared to $13.1 million for the fourth quarter of 2022.
  • Praxis incurred a net loss of $26.9 million for the fourth quarter of 2023, including $5.7 million of stock-based compensation expense, compared to $41.2 million for the fourth quarter of 2022, including $6.4 million of stock-based compensation expense.

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024
Research, FOS, FDA, Pain, Food, Drug discovery, SCN8A, Epilepsy, Safety, SCN1A, Neurocrine Biosciences, Nav1.7, Webcast, Depression, Patient, OLE, KV7, DSM-IV codes, MDD, IND, NDA, Ageing, Neurology, Pharmaceutical industry

VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • We also continue to evaluate other neurological indications that present a potential fit for XEN1101’s novel mechanism and product profile.
  • Other income was $8.7 million for the fourth quarter of 2023, and $31.4 million for the year ended 2023, compared to $7.1 million and $3.9 million for the same periods in 2022.
  • Net loss was $44.7 million for the fourth quarter of 2023, and $182.4 million for the year ended 2023, compared to $37.4 million and $125.4 million for the same periods in 2022, respectively.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its fourth quarter and full year 2023 results.

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024

Retrieved on: 
Monday, January 8, 2024
SCN1A, Drug discovery, DSM-IV codes, IND, Nav1.7, Depression, Epilepsy, FOS, Pain, SCN8A, Ageing, KV7, Food, Neurocrine Biosciences, MDD, Patient, Safety, OLE, Channel modulator, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 08, 2024 (GLOBE NEWSWIRE) --  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined progress within its pipeline programs and key milestones for 2024.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 08, 2024 (GLOBE NEWSWIRE) --  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined progress within its pipeline programs and key milestones for 2024.
  • Xenon anticipates that patient enrollment in X-TOLE2 will be completed in the second half of 2024.
  • Xenon is actively assessing various clinical and regulatory pathways to support late-stage clinical development of XEN1101 in MDD and expects to initiate the Phase 3 clinical program in 2024.
  • The near-term focus is on development candidates targeting Kv7, Nav1.1 and Nav1.7 where Xenon expects multiple candidates will enter IND-enabling studies in 2024 and 2025.

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Retrieved on: 
Tuesday, November 28, 2023
Molecule, Clinical trial, Audiogenic, Conference, PAME, Drug discovery, EEG, SCN2A, Drug development, Cerebrum, DEE, AES, Mortality, American Epilepsy Society, SCN8A, Standard of care, Pharmacokinetics, Annual general meeting, CNS, Part, Biomarker, Family Gathering, Generalized tonic–clonic seizure, Central nervous system, Patient, Safety, BTS, ASM, MES, Pharmaceutical industry

Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.

Key Points: 
  • Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.
  • ET [Platform D | Epilepsy Therapies]
    Summary: Combined preclinical and clinical data demonstrate PRAX-628 is differentiated from standard of care, with the potential to be best-in-class for focal epilepsy.
  • Summary: This study provides novel insights into the clinical validity of commonly used preclinical seizure models across the clinical epilepsy spectrum.
  • Oral presentation highlighting clinical updates from our PRAX-562 small molecule platform at the annual clinician, researcher, and family gathering for SCN8A

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023
Research, MADRS, Ageing, MDD, DBP, DSM-IV codes, Icahn School of Medicine at Mount Sinai, Neurocrine, Neurocrine Biosciences, JAMA Neurology, OLE, MPC, Mount Sinai, SCN8A, Webcast, Seizure, FOS, Safety, Epilepsy, Generalized tonic–clonic seizure, Patient, Grammatical mood, Pharmaceutical industry, Cryptocurrency, Xenon

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Xenon anticipates that patient enrollment in X-TOLE2 will be completed in the second half of 2024.
  • Other income for the quarter ended September 30, 2023 was $7.1 million, compared to $0.4 million for the same period in 2022.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its third quarter 2023 results.

Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress

Retrieved on: 
Thursday, August 31, 2023
Epilepsy, Central nervous system, Pharmacodynamics, SCN8A, Quality of life, CNS, SCN2A, Patient, Pharmacokinetics, Generalized tonic–clonic seizure, IEC, Pharmaceutical industry, Tolerability, Safety, Praxis

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will present data from two of its clinical-stage epilepsy programs at the upcoming 35th International Epilepsy Congress (IEC), to be held on September 2-6, 2023 in Dublin, Ireland.

Key Points: 
  • BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will present data from two of its clinical-stage epilepsy programs at the upcoming 35th International Epilepsy Congress (IEC), to be held on September 2-6, 2023 in Dublin, Ireland.
  • “There remains a great unmet need in epilepsy for anti-seizure medications that restore quality of life to patients and their families, and we are committed to developing best-in-class treatment options for both rare and prevalent epilepsies,” said Marcio Souza, president and chief executive officer of Praxis.
  • “Data from our Phase 1 study of PRAX-628 for focal epilepsy support a potentially best-in-class safety profile that could address the limitations of existing therapies, such as poor tolerability and dose-limiting titration requirements.
  • We look forward to presenting data from this program along with data from our PRAX-562 program for children with SCN2A and SCN8A developmental and epileptic encephalopathies.”
    PRAX-562-101: A First-in-Human Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of PRAX-562 in Healthy Volunteers
    PRAX-562-102: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-562 in Healthy Volunteers
    Safety, Tolerability and Pharmacokinetic Findings from a First-in-Human, Randomized, Double-Blinded, Placebo-Controlled Trial of Single and Multiple Ascending Doses of PRAX-628 in Healthy Participants

Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 9, 2023
Epilepsy, MPC, Icahn School of Medicine at Mount Sinai, DBP, SCN8A, Neurocrine Biosciences, DSM-IV codes, Neurocrine, Research, Mount Sinai, MADRS, FOS, MDD, Patient, Grammatical mood, Seizure, Webcast, Ageing, KV, OLE, Safety, Medical device, Pharmaceutical industry, Cryptocurrency, Xenon

VANCOUVER, British Columbia, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • Xenon to host XEN1101 MDD Webinar in mid-September to discuss Kv modulation in MDD, the X-NOVA clinical trial and the broader MDD landscape
    VANCOUVER, British Columbia, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • Research and development expenses for the quarter ended June 30, 2023 were $44.0 million, compared to $22.1 million for the same period in 2022.
  • Net loss for the quarter ended June 30, 2023 was $47.5 million, compared to $31.2 million for the same period in 2022.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its second quarter 2023 results.

Briefing on Capitol Hill Urges More Government Action and Investment in the Epilepsies

Retrieved on: 
Wednesday, May 24, 2023
Epilepsy, Seizure, FY, Capitol Hill, Traumatic brain injury, Research program, SCN8A, Quality of life, Human, Tuberous sclerosis, Research, Child, Doctor of Philosophy, Government, Organization, TSC, Congress, National Hospital for Neurology and Neurosurgery, Children's National Hospital, Patient, Epilepsy Foundation, Tuberous sclerosis complex tumor suppressors, Fiscal year, Letter, Neurology, Pharmaceutical industry, SUDEP

WASHINGTON, May 24, 2023 /PRNewswire/ -- In cooperation with the Congressional Epilepsy Caucus, organizations including the Epilepsy Foundation, Epilepsies Action Network, CURE Epilepsy, Rare Epilepsy Network and DEE-P Connections hosted a briefing on Capitol Hill on May 17 to educate about the epilepsies and call for more government action and investment in the epilepsies.

Key Points: 
  • WASHINGTON, May 24, 2023 /PRNewswire/ -- In cooperation with the Congressional Epilepsy Caucus, organizations including the Epilepsy Foundation, Epilepsies Action Network, CURE Epilepsy, Rare Epilepsy Network and DEE-P Connections hosted a briefing on Capitol Hill on May 17 to educate about the epilepsies and call for more government action and investment in the epilepsies.
  • (R-NC-3) and Jim Costa (D-CA-21) spoke about their personal connections to epilepsy and the importance of the caucus.
  • "My son developed epilepsy when he was 14 and it took us months to get the right treatment for him," said Congressman Murphy.
  • The annual total healthcare burden for people living with the epilepsies and/or seizures is at least $54 billion.

Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
Epilepsy, EPIK, MPC, Icahn School of Medicine at Mount Sinai, DBP, Clinical trial, Neurocrine Biosciences, DSM-IV codes, Neurocrine, SCN8A, Research, Mount Sinai, ID, MADRS, FOS, MDD, Patient, Grammatical mood, Seizure, Webcast, Ageing, FDA, OLE, Safety, Nursing, Pharmaceutical industry, Video game, Xenon

VANCOUVER, British Columbia, May 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • VANCOUVER, British Columbia, May 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
  • We expect patient screening to be completed in June with the release of topline data in the fourth quarter.
  • No revenue was recognized in the first quarter of 2023, compared to $8.8 million for the same period in 2022.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its first quarter 2023 results.

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 1, 2023
KCNQ2, Mount Sinai, Patient, MADRS, Seizure, SCN8A, DBP, Grammatical mood, Channel modulator, Icahn School of Medicine at Mount Sinai, MRI, Ageing, Epilepsy, Depression, Neurocrine Biosciences, MDD, MPC, DSM-IV codes, FOS, OLE, EPIK, Magnetic resonance, SLC6A1 epileptic encephalopathy, Safety, Webcast, Research, Anhedonia, Physician, ID, Pharmaceutical industry, Cryptocurrency, Xenon

BURNABY, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • BURNABY, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
  • Topline results from the X-NOVA study are anticipated in the third quarter of this year.
  • No revenue was recognized in the fourth quarter of 2022, and $9.4 million for the year ended 2022, compared to $3.7 million and $18.4 million for the same periods in 2021, respectively.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its fourth quarter and full year 2022 results.